| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
0.100 | GeneticVariation | BEFREE | These data suggest that Asian populations have a significantly lower prevalence of codon 751 Lys/Gln polymorphism in XPD, which could be a key determinant for good response to oxaliplatin-based treatment and favorable outcomes. | 19432884 | 2009 |
||||
|
0.100 | GeneticVariation | BEFREE | For the single nucleotide polymorphisms in XRCC1 exon 10 (Arg399Gln, G/A) and XPD exon 23 (Lys751Gln, A/C), no remarkable differences for genotype distribution and allele frequencies were observed between BC group and control group in the study. | 18415712 | 2008 |
||||
|
0.100 | GeneticVariation | BEFREE | No clear association between XPD Asp312Asn or XPD Lys751Gln gene polymorphisms and lung cancer was found. | 15615908 | 2005 |
||||
|
0.100 | GeneticVariation | BEFREE | We assessed polymorphisms in the aryl hydrocarbon receptor (AhR-Arg554Lys), null variants of the glutathione S-transferase superfamily (GSTM1 and GSTT1), x-ray repair cross-complementing 1 and 3, and Xeroderma pigmentosum, group D (XRCC1-Arg399Gln, XRCC3-Thr241Met, XPD-Lys751Gln). | 15459223 | 2004 |
||||
|
0.100 | GeneticVariation | BEFREE | We investigated the genetic basis for these findings by analysing the Asp312Asn and Lys751Gln polymorphisms of the XPD (ERCC2) DNA repair gene in the same subjects. | 14735199 | 2004 |
||||
|
0.100 | GeneticVariation | BEFREE | To determine whether the XRCC1 (codon Arg399Gln) and XPD (codon Asp312Asn and codon Lys751Gln) polymorphisms are associated with prostate cancer susceptibility, we genotyped these polymorphisms in a primarily Caucasian sample of 506 sibships (n = 1,117) ascertained through a brother with prostate cancer. | 14744728 | 2004 |
||||
|
0.100 | GeneticVariation | BEFREE | No association was found between p53 mutations and either XPD Lys751Gln or XRCC1 Arg399Gln. | 12844488 | 2003 |
||||
|
0.100 | GeneticVariation | BEFREE | We conclude that XPD Lys751Gln polymorphism may be an important marker in the prediction of clinical outcome to platinum-based chemotherapy. | 11751380 | 2001 |